NCT04993339View on ClinicalTrials.gov

Clinical Outcomes of ACL Reconstruction Augmented by an Injectable Osteoconductive/Osteoinductive Compound

PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 24, 2016

Primary Completion Date

February 20, 2020

Study Completion Date

February 20, 2020

Conditions
ACL Injury
Interventions
DRUG

OOC

The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels

Trial Locations (1)

33146

University of Miami, Coral Gables

Sponsors

Collaborators (1)

Arthrex, Inc.
All Listed Sponsors
collaborator

Arthrex, Inc.

INDUSTRY

lead

University of Miami

OTHER

NCT04993339 - Clinical Outcomes of ACL Reconstruction Augmented by an Injectable Osteoconductive/Osteoinductive Compound | Biotech Hunter | Biotech Hunter